comprehensive -WSS

comprehensive

author：explore 2025-08-12 08:26:01 - browse：317

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Nick Jonas talks about managing diabetes along with his career

focus

WSS

A fraught question for the kids of Alzheimer’s: Is it coming for us?

FDA scientists endorse Pfizer/BioNTech Covid

Massive project maps cells in human brain in unprecedented detail

Massive project maps cells in human brain in unprecedented detail

How doctors and nurses shape Google's AI

FDA approves Sage Therapeutics’ rapid

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

STAT Readout: Today's biotech news includes Sana and Amylyx

Apple is now the first public company to be valued at $3 trillion

Medicare slashes safety net hospital payments by nearly $1 billion

Novavax promises a turnaround & Lilly roils the obesity market

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Continuity nursing helped my family in our darkest PICU moments

Physicians aren't 'burning out.' They're suffering from moral injury

Walensky prepares to leave CDC — and Congress — behind

Study links childhood stress with decline in older age

Wikipedia

Physicians aren't 'burning out.' They're suffering from moral injury

Late stage cancers on the rise after pandemic delayed screenings

How doctors and nurses shape Google's AI

A fraught question for the kids of Alzheimer’s: Is it coming for us?

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Biotech startup Celsius cuts 75% of staff ahead of first trial start

hotspot

focus

Wikipedia

knowledge